- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
United States Department of Health and Human Services Publishes New HIV Treatment Guidelines Including Trogarzo
Theratechnologies (TSX:TH) is pleased to announce that Trogarzo (ibalizumab-uiyk) injection is now included in the most recent version of the treatment guidelines issued by the United States Department of Health and Human Services. As quoted in the press release: The DHHS guidelines state that “Patients with ongoing detectable viremia who lack sufficient treatment options to construct …
Theratechnologies (TSX:TH) is pleased to announce that Trogarzo (ibalizumab-uiyk) injection is now included in the most recent version of the treatment guidelines issued by the United States Department of Health and Human Services.
As quoted in the press release:
The DHHS guidelines state that “Patients with ongoing detectable viremia who lack sufficient treatment options to construct a fully suppressive regimen may be candidates for the recently approved CD4 post-attachment inhibitor ibalizumab.”
“We are very pleased with these guidelines. They recognize the unique mode of action of Trogarzo® and they confirm its usefulness in patients who cannot decrease their viral load below detection despite being on other antiretrovirals. The DHHS guidelines should give even more traction with physicians and payers in the United States,” said Luc Tanguay, President and CEO, Theratechnologies Inc.
“After the publication of treatment guidelines by the International Antiviral Society and the publication of the phase III clinical trial results in the New England Journal of Medicine, this is yet another major milestone for Trogarzo® which should generate even more interest in the product and support sales,” added Mr. Tanguay.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.